Triochem Products Peer Comparison

BSE: 512101

₹17.40

₹0.30 (1.75%)

As on 24-Sep-2015IST

Market cap

₹0 Cr

Revenue (TTM)

₹0 Cr

P/E Ratio

--

P/B Ratio

0.1

Div. Yield

0 %

Edit

	Triochem Products	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Market cap (₹ Cr)	0	33,911	29,031	28,149	27,692
Revenue (₹ Cr)	--	3,564	1,936	1,462	9,205
Net Profit (₹ Cr)	8.10	414.00	288.22	387.35	-371.81
Net Margin (%)	999.63	11.23	14.79	26.01	-3.93
RoE (%)	-2.10	8.38	29.77	25.18	-3.85
Price to Earnings	--	82.91	100.73	72.88	--
Price-To-Book	0.10	6.74	21.63	16.31	3.46

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Triochem Products	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Operating Revenue	0.00	3,564.00	1,935.80	1,461.80	9,205.28
Total Income	0.81	3,686.00	1,948.58	1,489.25	9,449.59
Total Expenditure	1.07	2,792.00	1,485.56	919.25	8,195.15
EBITDA	-1.07	772.00	450.24	542.56	1,010.13
Depreciation	0.03	226.00	50.83	37.68	857.51
EBIT	-1.10	546.00	399.41	504.88	152.62
Interest	0.08	217.00	40.84	3.77	342.73
Other Income	0.81	122.00	12.78	27.45	244.31
Exceptional Items	11.17	12.00	0.00	0.00	-216.88
Profit before Tax	10.80	463.00	371.35	528.56	-162.68
Provision for Tax	2.70	49.00	83.14	141.21	209.13
Profit after Tax	8.10	414.00	288.22	387.35	-371.81

Liabilities (₹ Cr)

	Triochem Products	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Shareholder's Funds	20.65	4,940.00	1,288.82	1,653.56	8,162.62
Minority Interest	0.00	-5.00	0.00	-1.13	0.00
Non-Current Liabilities	0.20	1,712.00	202.03	42.40	5,044.14
Current Liabilities	0.03	1,622.00	835.87	230.82	4,758.28
Total Liabilities	20.88	8,578.00	2,326.71	1,983.96	17,723.32

Assets (₹ Cr)

	Triochem Products	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Non-Current Assets	7.89	5,343.00	519.60	1,026.85	10,211.52
Current Assets	12.99	2,606.00	1,681.81	881.27	7,191.66
Total Assets	20.88	8,578.00	2,326.71	1,983.96	17,723.32
Total Debt*	0.00	2,125.00	259.37	26.49	5,495.48
Net Current Assets	12.96	984.00	845.94	650.46	2,433.38
Contingent Liabilities	0.03	768.26	19.09	17.25	95.72

Cashflow (₹ Cr)

	Triochem Products	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Cash From Operating Activities	-2.87	390.00	205.05	292.17	1,652.60
Cash Flow from Investing Activities	13.70	-241.00	-409.72	-265.94	-826.03
Cash from Financing Activities	--	-54.00	283.07	4.10	-38.98
Net Cash Inflow / Outflow	10.82	95.00	78.39	30.33	787.59

Ratios

Profitability Ratios

	Triochem Products	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
ROCE (%)	61.90	6.79	29.22	32.42	1.24
ROE (%)	-2.10	8.38	29.77	25.18	-3.85
ROA (%)	46.57	4.94	24.77	21.93	-2.21
EBIT Margin (%)	--	15.32	20.63	34.54	1.66
Net Margin (%)	999.63	11.23	14.79	26.01	-3.93
Cash Profit Margin (%)	--	0.00	0.00	0.00	0.00

Growth Ratios

	Triochem Products	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Revenue Growth (%)	--	18.37	46.65	40.90	0.78
EBIT Growth (%)	33.87	252.26	62.13	124.50	-70.53
Net Profit Growth (%)	1,983.02	377.85	89.49	104.15	-1,383.43
EPS Growth (%)	15.74	1,001.33	78.60	42.32	-484.84
Book Value Growth (%)	51.08	13.47	144.31	26.03	0.33

Valuation Ratios

	Triochem Products	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Price / Earnings	0.00	85.10	99.18	72.88	-88.50
Price / Book Value	0.00	6.74	21.63	16.31	3.46
Dividend Yield (%)	--	0.00	0.09	0.07	0.00
EV/EBITDA	22.99	45.82	64.29	51.52	31.51
Market Cap (₹ Cr)	--	19,071.62	12,753.19	20,944.75	18,108.89

Solvency Ratios

	Triochem Products	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debt to Equity	0.00	0.31	0.11	0.02	0.53
Short term debt to equity ratio	--	0.09	0.05	0.02	0.09
Current Ratio	405.97	1.61	2.01	3.82	1.51
Quick Ratio	405.97	1.06	1.14	2.82	0.87
Interest Coverage	137.65	3.13	10.09	141.16	0.53

Operating Efficiency Ratios

	Triochem Products	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debtors to sales (%)	--	16.50	26.28	24.80	23.44
Asset Turnover	0.00	0.43	1.66	0.83	0.55
Receivable days	--	58.75	40.13	88.98	78.20
Inventory Days	--	75.82	60.29	56.04	93.30
Payable days	--	186.21	232.47	99.95	226.14
Cash Conversion Cycle	--	-51.64	-132.04	45.07	-54.64

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly